{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:23:45Z","timestamp":1788535425569,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP190103486"],"award-info":[{"award-number":["DP190103486"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.nano.2021.102369","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T23:43:30Z","timestamp":1614123810000},"page":"102369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment"],"prefix":"10.1016","volume":"34","author":[{"given":"Li","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity Y.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"69","key":"10.1016\/j.nano.2021.102369_bb0005","first-page":"363","article-title":"Cancer treatment and survivorship statistics","volume":"2019","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.nano.2021.102369_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/wnan.1353","article-title":"Combinatorial nanomedicines for colon cancer therapy","volume":"8","author":"Anitha","year":"2016","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.nano.2021.102369_bb0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(95)90696-7","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.nano.2021.102369_bb0020","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.bjc.6600185","article-title":"Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity","volume":"86","author":"Fischel","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nano.2021.102369_bb0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199002083220602","article-title":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","volume":"322","author":"Moertel","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2021.102369_bb0030","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/bjc.1998.225","article-title":"Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma","volume":"77","author":"Scheithauer","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nano.2021.102369_bb0035","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/mt.2011.174","article-title":"A double-modulation strategy in cancer treatment with a chemotherapeutic agent and sirna","volume":"19","author":"Nakamura","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.nano.2021.102369_bb0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (napoli-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nano.2021.102369_bb0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2016.06.012","article-title":"Nanomedicine of synergistic drug combinations for cancer therapy \u2014 strategies and perspectives","volume":"240","author":"Zhang","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2021.102369_bb0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0163-7258(91)90086-2","article-title":"The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics","volume":"52","author":"Rowinsky","year":"1991","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nano.2021.102369_bb0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbcan.2007.10.004","article-title":"Taxanes, microtubules and chemoresistant breast cancer","volume":"1785","author":"McGrogan","year":"2008","journal-title":"Biochim. Biophys. Acta, Rev. Cancer"},{"key":"10.1016\/j.nano.2021.102369_bb0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc1566","article-title":"Cancer nanotechnology: opportunities and challenges","volume":"5","author":"Ferrari","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2021.102369_bb0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2021.102369_bb0070","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3k\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nano.2021.102369_bb0075","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1021\/ja512616s","article-title":"Improving paclitaxel delivery: in vitro and in vivo characterization of pegylated polyphosphoester-based nanocarriers","volume":"137","author":"Zhang","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nano.2021.102369_bb0080","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.bjc.6601303","article-title":"Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens","volume":"90","author":"Kloover","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.nano.2021.102369_bb0085","first-page":"1947","article-title":"Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3k\/mTOR dual inhibitor bez235 through apoptosis","volume":"11","author":"Zou","year":"2016","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2021.102369_bb0090","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3389\/fphar.2018.00582","article-title":"Human albumin fragments nanoparticles as ptx carrier for improved anti-cancer efficacy","volume":"9","author":"Ge","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nano.2021.102369_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000443371","article-title":"A combination of targeted therapy with chemotherapy backbone induces response in a treatment-resistant triple-negative MCL1-amplified metastatic breast cancer patient","volume":"9","author":"Ali","year":"2016","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.nano.2021.102369_bb0100","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-Trop-2 antibody-sn-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nano.2021.102369_bb0105","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jconrel.2016.04.018","article-title":"Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy","volume":"240","author":"Wang","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2021.102369_bb0110","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41563-018-0147-9","article-title":"Biomaterial-assisted targeted modulation of immune cells in cancer treatment","volume":"17","author":"Wang","year":"2018","journal-title":"Nat Mater"},{"key":"10.1016\/j.nano.2021.102369_bb0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17425247.2016.1205583","article-title":"Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy","volume":"14","author":"Xiao","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.nano.2021.102369_bb0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00216-018-1401-3","article-title":"Profiling of nanoparticle\u2013protein interactions by electrophoresis techniques","volume":"411","author":"Zarei","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.nano.2021.102369_bb0125","article-title":"Integrating fluorinated polymer and manganese-layered double hydroxide nanoparticles as pH-activated 19F MRI agents for specific and sensitive detection of breast cancer","volume":"15","author":"Zhang","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.nano.2021.102369_bb0130","doi-asserted-by":"crossref","first-page":"20326","DOI":"10.1021\/acsami.8b04613","article-title":"Brain targeting delivery facilitated by ligand-functionalized layered double hydroxide nanoparticles","volume":"10","author":"Chen","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.nano.2021.102369_bb0135","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.biomaterials.2013.12.095","article-title":"Co-delivery of siRNA and anti-cancer drugs using layered double hydroxide nanoparticles","volume":"35","author":"Li","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2021.102369_bb0140","first-page":"3403","article-title":"Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3k\/mTOR dual inhibitor BEZ-235 through apoptotic pathways","volume":"9","author":"Chen","year":"2014","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2021.102369_bb0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcis.2016.02.042","article-title":"Efficient drug delivery using SiO2-layered double hydroxide nanocomposites","volume":"470","author":"Li","year":"2016","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.nano.2021.102369_bb0150","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1039\/C5TB00248F","article-title":"Pre-coating layered double hydroxide nanoparticles with albumin to improve colloidal stability and cellular uptake","volume":"3","author":"Gu","year":"2015","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.nano.2021.102369_bb0155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou\u2013Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2021.102369_bb0160","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1002\/adfm.201601341","article-title":"BSA-mediated synthesis of bismuth sulfide nanotheranostic agents for tumor multimodal imaging and thermoradiotherapy","volume":"26","author":"Wang","year":"2016","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.nano.2021.102369_bb0165","doi-asserted-by":"crossref","first-page":"180549","DOI":"10.1155\/2014\/180549","article-title":"Protein nanoparticles as drug delivery carriers for cancer therapy","volume":"2014","author":"Lohcharoenkal","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.nano.2021.102369_bb0170","doi-asserted-by":"crossref","first-page":"1000184","DOI":"10.4172\/2157-7439.1000184","article-title":"Use of nanotechnology to develop multi-drug inhibitors for cancer therapy","volume":"4","author":"Gowda","year":"2013","journal-title":"J Nanomed Nanotechnol"},{"key":"10.1016\/j.nano.2021.102369_bb0175","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/ncb1106-1213","article-title":"ROS as a tumour suppressor?","volume":"8","author":"Ramsey","year":"2006","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.nano.2021.102369_bb0180","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/ncb1491","article-title":"Mitogenic signalling and the p16INK4a\u2013Rb pathway cooperate to enforce irreversible cellular senescence","volume":"8","author":"Takahashi","year":"2006","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.nano.2021.102369_bb0185","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.08.015","article-title":"Reactive oxygen species in cancer cells: live by the sword, die by the sword","volume":"10","author":"Schumacker","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nano.2021.102369_bb0190","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1089\/ars.2011.4414","article-title":"Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy","volume":"16","author":"Gupta","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.nano.2021.102369_bb0195","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ajpath.2010.10.029","article-title":"Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model","volume":"178","author":"Bao","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.nano.2021.102369_bb0200","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.bbagen.2014.06.004","article-title":"Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment","volume":"1840","author":"Anitha","year":"2014","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.nano.2021.102369_bb0205","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10717544.2019.1660733","article-title":"Syl3c aptamer-anchored microemulsion co-loading \u03b2-elemene and PTX enhances the treatment of colorectal cancer","volume":"26","author":"Zhou","year":"2019","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2021.102369_bb0210","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1039\/C9TB00181F","article-title":"Albumin enhances PTX delivery ability of dextran NPs and therapeutic efficacy of PTX for colorectal cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.nano.2021.102369_bb0215","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1038\/ncomms8939","article-title":"A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms abraxane in multiple murine cancer models","volume":"6","author":"Bhattacharyya","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2021.102369_bb0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biomaterials.2018.05.055","article-title":"Novel theranostic nanoplatform for complete mice tumor elimination via mr imaging-guided acid-enhanced photothermo-\/chemo-therapy","volume":"177","author":"Li","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2021.102369_bb0225","first-page":"1","article-title":"Charge reversion simultaneously enhances tumor accumulation and cell uptake of layered double hydroxide nanohybrids for effective imaging and therapy","volume":"16","author":"Liu","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.nano.2021.102369_bb0230","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1021\/acsanm.8b00410","article-title":"Combining magnetic resonance imaging with photothermal therapy of CuS@BSA nanoparticles for cancer theranostics","volume":"1","author":"Chu","year":"2018","journal-title":"ACS Appl Nano Mater"},{"key":"10.1016\/j.nano.2021.102369_bb0235","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.7150\/thno.19365","article-title":"Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery","volume":"7","author":"An","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.nano.2021.102369_bb0240","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2021.102369_bb0245","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/jnci\/88.18.1308","article-title":"Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel","volume":"88","author":"Milross","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nano.2021.102369_bb0250","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1083\/jcb.135.3.689","article-title":"Differential taxol-dependent arrest of transformed and nontransformed cells in the g1 phase of the cell cycle, and specific-related mortality of transformed cells","volume":"135","author":"Trielli","year":"1996","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nano.2021.102369_bb0255","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J","article-title":"Paclitaxel-induced cell death","volume":"88","author":"Wang","year":"2000","journal-title":"Cancer"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963421000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963421000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:15:44Z","timestamp":1761549344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963421000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":51,"alternative-id":["S1549963421000125"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2021.102369","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2021.102369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102369"}}